Azitra

Farmington, United States Founded: 2014 • Age: 12 yrs Listed
Microbiome-based therapeutics for skin conditions like eczema are developed.

About Azitra

Azitra is a publicly listed company based in Farmington (United States) founded in 2014. Microbiome-based therapeutics for skin conditions like eczema are developed. Azitra has raised $37.4 million across 11 funding rounds from investors including HHS, Connecticut Innovations and Bios Partners. The company has 12 employees. Its chief executive, as recorded, is Francisco Salva. Azitra offers products and services including ATR-12, ATR-04, and ATR-01. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Azitra was founded in 2014 and is headquartered in Farmington, United States, within the biotechnology sector. Focus is placed on microbiome-derived solutions for dermatological disorders, including atopic dermatitis and eczema. The lead candidate, AZT-04, addresses rashes associated with cancer therapies, while preclinical programs encompass AZT-01 for filaggrin delivery in eczema treatment and ATR-12, featuring engineered Staphylococcus epidermidis for LEKTI expression in Netherton syndrome. Operations remain centered on therapeutic development.

  • Headquarters Farmington, United States
  • Employees 12
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website azitrainc.com
  • Social LinkedIn X
  • Legal Name Azitra Inc
Key Metrics
  • Net Profit
    -$10.96 M (USD)
    -22.17
    as on Dec 31, 2025
  • EBITDA
    -$10.51 M (USD)
    -4.15
    as on Dec 31, 2025
  • Total Equity Funding
    $37.4M (USD)

    in 11 rounds

  • Latest Funding Round
    $1M (USD), Series B

    Jan 2021

  • Investors
    HHS

    & 6 more

  • Employee Count
    12

Products & Services of Azitra

Azitra offers a comprehensive portfolio of products and services, including ATR-12, ATR-04, and ATR-01.

ATR-12
Biotherapeutic

Engineered microbe for treating Netherton syndrome via microbial delivery.

ATR-04
Biotherapeutic

Auxotrophic microbe to manage EGFR inhibitor-associated rashes effectively.

ATR-01
Protein Therapeutic

Filaggrin protein for addressing ichthyosis vulgaris symptoms.

Funding Insights of Azitra

Azitra has successfully raised a total of $37.4M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $1 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $37.4M
  • Total Rounds 11
  • Last Round Series B β€” $1M
  • First Round $150,000

    (Aug 2016)

  • Investors Count 7

Latest 10 of 11 funding rounds of Azitra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2021$1MSeries B––
–
Sep 2020$17MSeries B–Leaps by Bayer
Oct 2019$14MSeries A–Bios Partners, KdT Ventures
Apr 2019$719,727Grant––
Sep 2018Grant––
Aug 2018$225,000Grant––
May 2018$2.15MSeries A–Connecticut Innovations
Mar 2017$2.9MSeries A–Bios Partners
–
Jan 2017$225,000Grant––
Oct 2016$350,000Seed–Breakout Labs
–
Valuation history

7 investors in total: 7 institutional.

Investors in Azitra

Azitra has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Connecticut Innovations and Bios Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
ctinnovations.com
Venture capital is provided by Bios Partners for biotech innovation.
2017biospartners.comFort Worth, United States
Venture capital firm investing in life sciences sector
leaps.bayer.comLeverkusen, Germany
Early-stage investments are made in frontier science ventures.
kdtvc.comBlack Mountain, United States
Early-stage science-driven companies are supported through venture capital investments.
breakoutlabs.org
Public health and human services are overseen by HHS.
1953hhs.gov
Military forces are provided by the U.S. Department of Defense for national security.
defense.govWashington, D.C., United States
Premium access

Investor details for Azitra

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Azitra

11 people are tracked at Azitra (6 in leadership, 5 in board & advisors); the tracked headcount is 12.

NameRoleGroup
Francisco Salva
CEOLeadership
Travis Whitfill
Co-founder & Executive Director of Advanced TechnologyLeadership
Dorival Martins
Associate DirectorLeadership
Edward B. Punzalan
Director of GMP Manufacturing and Process DevelopmentLeadership
Roger Leger
VP of Chemistry, Formulation & DevelopmentLeadership
Peter F.
Director Of Facilities And OperationsLeadership
Julia Oh
Advisory BoardBoard & advisors
Jeffrey L. Bose
Advisory BoardBoard & advisors
Leonard Milstone
Advisory BoardBoard & advisors
Stella M. Roberston
DirectorBoard & advisors
Cain McClary
DirectorBoard & advisors
Premium access

Complete people profiles for Azitra

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Azitra

Azitra is a publicly listed company on the AMEX with ticker symbol AZTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Jun 2023
  • Listed onNYSEAMERICAN: AZTR
  • Listed entityAzitra Inc
  • Exchange sectorHealth technology
  • ISINUS05479L3024
  • Share price$0.07 (-39.2% on the day) · 2026-10-13
  • Market capitalisation$4.3M
  • EPS (diluted, trailing year)$-1.31
  • Volume (last session)2,670,553

Financials of Azitra

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$11.0M-$10.5M
2024$7,500-$9.0M-$10.1M
2023$686,000-$11.3M-$6.8M
2022$284,000-$10.7M-$9.1M
2021$110,000-$8.9M-$9.1M
Premium access

Detailed financial statements for Azitra

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Azitra

4 dated milestones of Azitra across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Azitra is founded.
  2. Funding First funding round of $150K.
  3. Funding Latest funding round, Series B, of $1.0M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Azitra

Azitra has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Azitra

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Azitra

The website of Azitra (azitrainc.com) receives about 5.8K visits a month.

  • Monthly visits
    5.8K

    ▲ 98.9% vs previous month

Similar websites

Websites whose visitors overlap most with Azitra. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
franklintransit.org
franklintransit.org
100%
#7,037,034–
azitra.com
azitra.com
87%
#2,668,023–
azitra.us
azitra.us
76%
–

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Azitra (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Azitra

Premium access

Complete news archive for Azitra

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Azitra

Azitra was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Azitra is headquartered in Farmington, United States.

Francisco Salva is the CEO of Azitra, as recorded in our data.

Azitra is a funded company, having raised a total of $37.4M across 11 funding rounds to date. The company's 1st funding round was a Seed of $350K, raised on Aug 2016.

Azitra has 12 employees.

Azitra was founded in 2014 and is headquartered in Farmington, United States, within the biotechnology sector. Focus is placed on microbiome-derived solutions for dermatological disorders, including atopic dermatitis and eczema. The lead candidate, AZT-04, addresses rashes associated with cancer therapies, while preclinical programs encompass AZT-01 for filaggrin delivery in eczema treatment and ATR-12, featuring engineered Staphylococcus epidermidis for LEKTI expression in Netherton syndrome. Operations remain centered on therapeutic development.

Azitra's top competitors include Moderna, BeiGene and Incyte.

Azitra offers ATR-12, ATR-04, and ATR-01.

Yes, Azitra is publicly traded on AMEX under the ticker symbol AZTR.

Azitra has 7 investors. Key investors include HHS, Connecticut Innovations, Bios Partners, Leaps by Bayer, and KdT Ventures.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available